CVAC CureVac Corp Projected Sales Volume

Official company branding of CureVac N.V. (CVAC)

Leveraging unique RNA platform patents and strict regulatory oversight, CureVac N.V. (CVAC) has established a protective moat based on an innovative vaccine architecture with optimized coding. The company's sales expectations reflect current trends, where 0.08 shows the actual metric value. CureVac N.V. (CVAC) is now transitioning to an autonomous development cycle, focusing on oncology therapies and emerging infections.

CureVac N.V. - CVAC Projected Sales Volume (period 07/04/2022 - 01/17/2026)

Summary analytical data breakdowns for CureVac N.V. (CVAC)

- stock value and consensus price forecast:
Price Chart CureVac NV|CVAC - Analyst Median Target
- market capitalization data:
Market Capitalization CureVac|CVAC - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value per Share CureVac|CVAC - Book Capitalization|Market Value to Book Value Ratio curevac.com|CVAC - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Capital CureVac N.V.|CVAC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio CureVac N.V.|CVAC - Company Debts|Debts to Book Capitalization CureVac Corp|CVAC - Company Long-Term Debts|Company Short-Term Debts CureVac|Quick Liquidity Indicator curevac.com
- financial results and valuation multiples details:
CVAC - Final Profit|Expected Profit CureVac N.V.|CVAC - Price to Earnings Multiple|Projected Price to Earnings CureVac Pharma|CVAC - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio CureVac Pharma|CVAC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months CureVac|CVAC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth curevac.com|CVAC - Net earnings per share growth this year|Expected earnings per share growth for next year CureVac N.V.
- sales volume and revenue indicators:
CVAC - Company Revenue|Projected Sales Volume curevac.com|CVAC - P/S Multiple|Forward P/S Multiple CureVac
General company analysis:curevac.com
Brand item of CureVac Pharma

This indicator aggregates market consensus estimates for future cash flows, filtering out short-term noise and capturing traders' actual revenue expectations. By analyzing the company's projected sales volumes, investors can track the trend of expected royalties and upfront payments from GSK, which is critical for assessing the commercialization of CureVac N.V. (CVAC) mRNA technologies within the vaccine and oncology segments.

Analysis of competing companies

Company Projected Revenue Gilead (GILD)|Company Future Sales Cidara Therapeutics Inc|Company Projected Revenue Novavax, Inc. NVAX|Valneva Pharma - Company Projected Revenue|VIR - Company Projected Revenue|Company Future Sales SIGA Technologies, Inc. SIGA|Emergent BioSolutions Inc. (EBS) - Company Projected Revenue|Company Expected Sales Volume Atea Pharmaceuticals, Inc. (AVIR)|IVVD (Invivyd) - Projected Sales Volume|Company Revenue Forecast ENTA (Enanta Pharmaceuticals)|Company Projected Revenue Inovio Pharmaceuticals, Inc. (INO)|HLVX - Company Expected Sales Volume|Projected Sales Volume KLRS (Kalaris Therapeutics Inc.)|DYAI - Company Future Sales Volume|NNVC - Company Projected Revenue|Company Future Revenue TLPH (Talphera Corp)|COCP: Projected Sales Volume|Traws Pharma Inc - Company Future Revenue|Company Future Sales Volume DWTX|QLGN: Company Future Revenue|Company Projected Revenue AlloVir Bio (ALVR)|VBI Vaccines - Company Revenue Forecast|Company Projected Revenue Virios Therapeutics VIRI|Company Future Sales vaxart.com (VXRT)